KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer
Published: | Updated:
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Charles E. Geyer Jr, MD
Advertisement
Articles by Charles E. Geyer Jr, MD
Advertisement
Latest Updated Articles
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast CancerPublished: December 12th 2018 | Updated: November 2nd 2022
Advertisement
Advertisement
Trending on CancerNetwork
1
Adding 177Lu-PSMA-617 to ADT Plus ARPI Improves Radiographic PFS in mHSPC
2
Potential Iberdomide Approval May Offer Another Choice in Multiple Myeloma
3
Adding SBRT to Ipilimumab/Nivolumab Does Not Improve PFS in Advanced RCC
4
Belzutifan Regimen Boosts Responses, PFS in Clear Cell RCC
5